Safinamide

🧮 Dose calculator

Parkinson's disease · Regimen source: FDA Xadago · 2.1

• • Moderate hepatic impairment: max 50 mg; severe: contraindicated. FDA Xadago · 2.2

Enter age (weight is optional for this regimen).

👥 Special populations

• 🤰 PregnancyUse with caution

  Label states no clear risk or has limited data; use only if needed, under medical advice. FDA Xadago · 8.1

  “Risk Summary There are no adequate data on the developmental risk associated with the use of XADAGO in pregnant women.”

• 🤱 BreastfeedingUse with caution

  Label: use with caution while breastfeeding; see the label text. FDA Xadago · 8.2

  “Risk Summary There is no information regarding the presence of XADAGO or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.”

• 👶 ChildrenSafety not established

  Label: safety and effectiveness in children have not been established. FDA Xadago · 8.4

  “Safety and effectiveness in pediatric patients have not been established.”

• 👴 Older adultsUse with caution

  Label: use with caution in older adults, usually starting at the low end of the dose range. FDA Xadago · 8.5

  “Of the 1516 subjects exposed to XADAGO in clinical studies, 38% were 65 and over, while 4% were 75 and over.”

• ⚥ Females & males of reproductive potentialNo data

  The source for this drug has no section for this group.